Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues in hyperparathyroidism.

Greg A Krempl1, Jesus E Medina

  • 1Department of Otorhinolaryngology, University of Oklahoma Health Sciences Center, P.O. Box 26902, WP1360, Oklahoma City, OK 73190, USA.

Otolaryngologic Clinics of North America
|June 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial.

International journal of radiation oncology, biology, physics·2026
Same author

The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.

Cancer research communications·2026
Same author

Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials.

JAMA otolaryngology-- head & neck surgery·2025
Same author

Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016.

International journal of radiation oncology, biology, physics·2025
Same author

Treatment of the neck in residual/recurrent disease after chemoradiotherapy for advanced primary laryngeal cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2024
Same author

Management of Recurrent Well-Differentiated Thyroid Carcinoma in the Neck: A Comprehensive Review.

Cancers·2023

Recent shifts in patient referrals mean surgeons increasingly see hypercalcemia instead of primary hyperparathyroidism. Accurate diagnosis involves history, lab tests, and urinary calcium levels to guide surgical treatment effectively.

Area of Science:

  • Endocrinology
  • Surgical Management
  • Diagnostic Medicine

Background:

  • Increasing referrals for hypercalcemia, not specifically primary hyperparathyroidism.
  • Need for clear diagnostic pathways for surgeons managing these patients.

Purpose of the Study:

  • To outline the diagnostic approach for patients presenting with hypercalcemia.
  • To guide surgeons in differentiating primary hyperparathyroidism from other causes.
  • To highlight the role of preoperative localization studies.

Main Methods:

  • Thorough patient history, including medication review.
  • Laboratory assessment: serum calcium and parathyroid hormone levels.
  • 24-hour urinary calcium excretion tests to exclude familial hypercalcemic hypocalciuria (FHH).

Related Experiment Videos

Main Results:

  • Diagnostic workup includes serum calcium, PTH, and urinary calcium.
  • Preoperative localization studies benefit 78-90% of patients diagnosed with primary hyperparathyroidism.
  • Sestamibi scan is the preferred localization method.

Conclusions:

  • A systematic approach is crucial for diagnosing primary hyperparathyroidism in patients referred for hypercalcemia.
  • Urinary calcium testing is essential for excluding FHH.
  • Preoperative localization significantly aids surgical planning and success.